Agenus Reports Q3 2025 Results Showcasing Clinical and Regulatory Advances
France grants reimbursed access with patients having commenced treatment Two-year BOT/BAL survival presented at ESMO spanning more than five cancers in over 400 patients Phase 3 on track to commence in fourth quarter 2025 LEXINGTON, Mass. — Agenus Inc. (Nasda
(Financial Post, 2025-11-10T12:39:31Z)